Serum fatty acid synthase and GLP-1 levels in prostate cancer and benign prostatic hyperplasia
Open Access
- 21 November 2025
- journal article
- research article
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 51 (3) , 405-410
Abstract
Objectives: This study aimed to investigate the differences in serum fatty acid synthase (FASN) and glucagon-like peptide-1 (GLP-1) levels among patients diagnosed with prostate cancer, benign prostatic hyperplasia (BPH), and healthy controls. Methods: A total of 60 male patients and 28 healthy male subjects were included in the study. Based on biopsy results, the patients were divided into two groups: prostate cancer (n=30) and BPH (n=30). Results: The mean FASN level was 6.71 ± 0.81 ng/mL in the prostate cancer group, 3.84 ± 0.21 ng/mL in the BPH group, and 3.57 ± 0.29 ng/mL in the control group. There was no statistically significant difference in FASN levels between the BPH and control groups (p>0.05). However, FASN levels were significantly higher in the prostate cancer group compared to both the control and BPH groups (p<0.001). The mean GLP-1 level was 9.69 ± 0.65 pmol/L in the prostate cancer group, 11.40 ± 0.77 pmol/L in the BPH group, and 7.03 ± 0.62 pmol/L in the control group. Compared to the control group, GLP-1 levels were significantly elevated in both the BPH and prostate cancer groups (p0.05). Conclusions: Our findings suggest that FASN and GLP-1 levels may contribute to the diagnostic accuracy of prostate diseases when used in conjunction with PSA and its derivatives.Keywords
This publication has 23 references indexed in Scilit:
- Analysis of fatty acid metabolism in prostate cancer and discovery of a new programmed cell death-associated luminal cell subpopulationDiscover Oncology, 2025
- Association between PSA density and pathologically significant prostate cancer: The impact of prostate volumeThe Prostate, 2020
- A Landscape of Metabolic Variation across Tumor TypesCell Systems, 2018
- Size Effect on Lipid Nanocapsule-Mediated GLP-1 Secretion from Enteroendocrine L CellsMolecular Pharmaceutics, 2017
- SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiologyNature Reviews Endocrinology, 2017
- Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancerCancer Letters, 2017
- Metabolic alterations and targeted therapies in prostate cancerThe Journal of Pathology, 2010
- Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β-catenin in prostate cancerLaboratory Investigation, 2008
- The Percentage of Free Prostatic-Specific Antigen Is Also Useful in Men with Normal Digital Rectal Examination and Serum Prostatic-Specific Antigen between 10.1 and 20 ng/mlEuropean Urology, 2002
- Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical ProstatectomyJournal of Urology, 1988